EPCAM and gastric cancer: As depicted in Fig. 2A, CSV+CTCs were detected in 95% of unresectable GC patients and 82% of resectable GC patients, whereas EpCAM+CTCs were observed in 45% of unresectable GC patients and 84% of resectable GC patients.